Adjuvant Pembrolizumab (NSCLC), Elacestrant, & Pirtobrutinib
OncoPharm
00:00
Comparing Pembrolizumab and Atezolizumab in Adjuvant NSCLC
John contrasts pembrolizumab and atezolizumab approvals, noting PD-L1 subgroup differences and potential PD-1 vs PD-L1 effects.
Play episode from 01:37
Transcript
